Seizures Associated with Zoledronic Acid for Osteoporosis | Zendy

Elena Tsourdi | Zendy; Tilman D. Rachner | Zendy; Matthias Grüber | Zendy; Christine Hamann | Zendy; Tjalf Ziemssen | Zendy; Lorenz C. Hofbauer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Seizures Associated with Zoledronic Acid for Osteoporosis

Author(s) -

Elena Tsourdi,

Tilman D. Rachner,

Matthias Grüber,

Christine Hamann,

Tjalf Ziemssen,

Lorenz C. Hofbauer

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-0418

Subject(s) - zoledronic acid , medicine , osteoporosis , context (archaeology) , bisphosphonate , pediatrics , paleontology , biology

Bisphosphonates represent potent antiresorptive drugs that are established for therapy of patients with benign and malignant bone diseases. Zoledronic acid is an iv aminobisphosphonate that is administered annually against osteoporosis. Because of its potency and the parenteral route of administration, zoledronic acid is an alternative to oral bisphosphonates, in particular in elderly patients with multiple comorbidities. The most common side effects include an acute-phase reaction and mild and transient hypocalcemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research